| Item Type | Name |
|
Concept
|
Survival
|
|
Concept
|
Survival Analysis
|
|
Concept
|
Survival Rate
|
|
Concept
|
Cell Survival
|
|
Concept
|
Disease-Free Survival
|
|
Academic Article
|
Carboplatin plus vinorelbine with concomitant radiation therapy in advanced non-small cell lung cancer: a phase I study.
|
|
Academic Article
|
Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck.
|
|
Academic Article
|
Functional organ preservation with definitive chemoradiotherapy for T4 laryngeal squamous cell carcinoma.
|
|
Academic Article
|
A phase II study of ABT-751 in patients with advanced non-small cell lung cancer.
|
|
Academic Article
|
A phase I trial of docetaxel based induction and concomitant chemotherapy in patients with locally advanced head and neck cancer.
|
|
Academic Article
|
The expanding role of systemic therapy in head and neck cancer.
|
|
Academic Article
|
Phase I study of bevacizumab added to fluorouracil- and hydroxyurea-based concomitant chemoradiotherapy for poor-prognosis head and neck cancer.
|
|
Academic Article
|
Chemoradiation for patients with advanced oral cavity cancer.
|
|
Academic Article
|
High survival and organ function rates after primary chemoradiotherapy for intermediate-stage squamous cell carcinoma of the head and neck treated in a multicenter phase II trial.
|
|
Academic Article
|
Epidermal growth factor receptor inhibitor gefitinib added to chemoradiotherapy in locally advanced head and neck cancer.
|
|
Academic Article
|
[18F]Fluorodeoxyglucose positron emission tomography in the initial staging of squamous cell carcinoma of the head and neck: promise, evidence, and reality.
|
|
Academic Article
|
Factors associated with long-term speech and swallowing outcomes after chemoradiotherapy for locoregionally advanced head and neck cancer.
|
|
Academic Article
|
A randomized phase II study of 5-fluorouracil, hydroxyurea, and twice-daily radiotherapy compared with bevacizumab plus 5-fluorouracil, hydroxyurea, and twice-daily radiotherapy for intermediate-stage and T4N0-1 head and neck cancers.
|
|
Academic Article
|
Phase II study of sunitinib malate in head and neck squamous cell carcinoma.
|
|
Academic Article
|
Efficacy and safety of treating T4 oral cavity tumors with primary chemoradiotherapy.
|
|
Academic Article
|
Predictors of competing mortality in advanced head and neck cancer.
|
|
Academic Article
|
Planned post-chemoradiation neck dissection: significance of radiation dose.
|
|
Academic Article
|
A phase II study of lapatinib in recurrent/metastatic squamous cell carcinoma of the head and neck.
|
|
Academic Article
|
Stereotactic body radiotherapy for multisite extracranial oligometastases: final report of a dose escalation trial in patients with 1 to 5 sites of metastatic disease.
|
|
Academic Article
|
Targeted and cytotoxic therapy in coordinated sequence (TACTICS): erlotinib, bevacizumab, and standard chemotherapy for non-small-cell lung cancer, a phase II trial.
|
|
Academic Article
|
Single sample expression-anchored mechanisms predict survival in head and neck cancer.
|
|
Academic Article
|
Factors associated with clinical benefit from epidermal growth factor receptor inhibitors in recurrent and metastatic squamous cell carcinoma of the head and neck.
|
|
Academic Article
|
Phase II study of gefitinib adaptive dose escalation to skin toxicity in recurrent or metastatic squamous cell carcinoma of the head and neck.
|
|
Academic Article
|
Phase II trial of gefitinib 250 mg daily in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck.
|
|
Academic Article
|
Induction chemotherapy and concurrent chemoradiotherapy for locoregionally advanced head and neck cancer: a multi-institutional phase II trial investigating three radiotherapy dose levels.
|
|
Academic Article
|
Adjuvant chemotherapy prior to postoperative concurrent chemoradiotherapy for locoregionally advanced head and neck cancer.
|
|
Academic Article
|
Effect of complementary pathway blockade on efficacy of combination enzastaurin and rapamycin.
|
|
Academic Article
|
Quality of life scores as prognostic factors of overall survival in advanced head and neck cancer: analysis of a phase III randomized trial of pemetrexed plus cisplatin versus cisplatin monotherapy.
|
|
Academic Article
|
Surrogate endpoints in head and neck cancer.
|
|
Academic Article
|
Cabozantinib for the treatment of advanced medullary thyroid cancer.
|
|
Academic Article
|
Outcomes of induction chemotherapy followed by concurrent chemoradiation for nasopharyngeal carcinoma.
|
|
Academic Article
|
Oral cavity tumors in younger patients show a poor prognosis and do not contain viral RNA.
|
|
Academic Article
|
Fluorescence in situ hybridization gene amplification analysis of EGFR and HER2 in patients with malignant salivary gland tumors treated with lapatinib.
|
|
Academic Article
|
Diastolic blood pressure as a biomarker of axitinib efficacy in solid tumors.
|
|
Academic Article
|
Phase III study of gefitinib compared with intravenous methotrexate for recurrent squamous cell carcinoma of the head and neck [corrected].
|
|
Academic Article
|
Survival and selected outcomes of older adults with locally advanced head/neck cancer treated with chemoradiation therapy.
|
|
Academic Article
|
DNA repair biomarkers XPF and phospho-MAPKAP kinase 2 correlate with clinical outcome in advanced head and neck cancer.
|
|
Academic Article
|
Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer.
|
|
Academic Article
|
A Phase II trial of axitinib in patients with various histologic subtypes of advanced thyroid cancer: long-term outcomes and pharmacokinetic/pharmacodynamic analyses.
|
|
Academic Article
|
Afatinib versus placebo as adjuvant therapy after chemoradiation in a double-blind, phase III study (LUX-Head & Neck 2) in patients with primary unresected, clinically intermediate-to-high-risk head and neck cancer: study protocol for a randomized controlled trial.
|
|
Academic Article
|
Cabozantinib in progressive medullary thyroid cancer.
|
|
Academic Article
|
Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial.
|
|
Academic Article
|
An open-label single-arm, phase II trial of zalutumumab, a human monoclonal anti-EGFR antibody, in patients with platinum-refractory squamous cell carcinoma of the head and neck.
|
|
Academic Article
|
Treatment of advanced thyroid cancer with axitinib: Phase 2 study with pharmacokinetic/pharmacodynamic and quality-of-life assessments.
|
|
Academic Article
|
Current Treatment Options for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma.
|
|
Academic Article
|
Phase II trial of dasatinib for recurrent or metastatic c-KIT expressing adenoid cystic carcinoma and for nonadenoid cystic malignant salivary tumors.
|
|
Academic Article
|
Erlotinib and the Risk of Oral Cancer: The Erlotinib Prevention of Oral Cancer (EPOC) Randomized Clinical Trial.
|
|
Academic Article
|
Importance of Radiation Oncologist Experience Among Patients With Head-and-Neck Cancer Treated With Intensity-Modulated Radiation Therapy.
|
|
Academic Article
|
Afatinib versus methotrexate in older patients with second-line recurrent and/or metastatic head and neck squamous cell carcinoma: subgroup analysis of the LUX-Head & Neck 1 trial.
|
|
Academic Article
|
Final Results of a Randomized Phase 2 Trial Investigating the Addition of Cetuximab to Induction Chemotherapy and Accelerated or Hyperfractionated Chemoradiation for Locoregionally Advanced Head and Neck Cancer.
|
|
Academic Article
|
Vemurafenib in patients with BRAF(V600E)-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial.
|
|
Academic Article
|
Correlative analyses of RET and RAS mutations in a phase 3 trial of cabozantinib in patients with progressive, metastatic medullary thyroid cancer.
|
|
Academic Article
|
Induction chemotherapy in locally advanced squamous cell carcinoma of the head and neck: role, controversy, and future directions.
|
|
Academic Article
|
Definitive chemoradiation for locally-advanced oral cavity cancer: A 20-year experience.
|
|
Academic Article
|
Biomarkers predict enhanced clinical outcomes with afatinib versus methotrexate in patients with second-line recurrent and/or metastatic head and neck cancer.
|
|
Academic Article
|
Effect of Adding Motolimod to Standard Combination Chemotherapy and Cetuximab Treatment of Patients With Squamous Cell Carcinoma of the Head and Neck: The Active8 Randomized Clinical Trial.
|
|
Academic Article
|
Afatinib as second-line treatment in patients with recurrent/metastatic squamous cell carcinoma of the head and neck: Subgroup analyses of treatment adherence, safety and mode of afatinib administration in the LUX-Head and Neck 1 trial.
|
|
Academic Article
|
Afatinib versus methotrexate as second-line treatment in Asian patients with recurrent or metastatic squamous cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 3): an open-label, randomised phase III trial.
|
|
Academic Article
|
SUPREME-HN: a retrospective biomarker study assessing the prognostic value of PD-L1 expression in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck.
|
|
Academic Article
|
Cost-effectiveness analysis of nivolumab for the treatment of squamous cell carcinoma of the head and neck in the United States.
|
|
Academic Article
|
B Cells Improve Overall Survival in HPV-Associated Squamous Cell Carcinomas and Are Activated by Radiation and PD-1 Blockade.
|
|
Academic Article
|
Quality of Life With Pembrolizumab for Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: KEYNOTE-040.
|
|
Academic Article
|
Talimogene Laherparepvec and Pembrolizumab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (MASTERKEY-232): A Multicenter, Phase 1b Study.
|
|
Academic Article
|
Comparing programmed death ligand 1 scores for predicting pembrolizumab efficacy in head and neck cancer.
|
|
Academic Article
|
Tipifarnib in recurrent, metastatic HRAS-mutant salivary gland cancer.
|
|
Academic Article
|
Role of B Cells in Responses to Checkpoint Blockade Immunotherapy and Overall Survival of Cancer Patients.
|
|
Academic Article
|
Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial.
|
|
Grant
|
Clinical translation of 19F MRI to visualize cancer immunotherapeutic cells
|